Ad Hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
Ad Hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
|
MorphoSys AG / Key word(s): Squeeze Out Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, July 12, 2024 Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00 MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Novartis BidCo Germany AG submitted a specified request (konkretisiertes Verlangen) to the MorphoSys AG Management Board, pursuant to section 62 para. 1 and 5 first sentence of the German Transformation Act (Umwandlungsgesetz - UmwG) in conjunction with sections 327a et seqq. of the German Stock Corporation Act (Aktiengesetz - AktG), to convene the MorphoSys AG's Annual General Meeting to resolve on the transfer of shares held by MorphoSys AG's minority shareholders to Novartis BidCo Germany AG against adequate cash compensation. Novartis BidCo Germany AG currently holds approximately 91.04% and, after deduction of the number of treasury shares pursuant to section 62 para. 1 sentence 2 UmwG, approximately 91.17% of the MorphoSys AG share capital and is therefore the major shareholder of MorphoSys AG as defined by section 62 para. 5 UmwG. Novartis BidCo Germany AG has determined the amount of the cash compensation to be EUR 68.00 per MorphoSys AG share. The court-appointed expert auditor has already indicated that, from a current standpoint, it will confirm the cash compensation to be adequate. The conclusion and notarization of the merger agreement between MorphoSys AG and Novartis BidCo Germany AG will take place shortly. At the MorphoSys AG Annual General Meeting, expected to take place on August 27, 2024, a resolution will be adopted on transferring MorphoSys AG minority shareholders' shares to Novartis BidCo Germany AG against a cash compensation of EUR 68.00 per share. The effectiveness of the merger squeeze-out is still subject to approval by the MorphoSys AG Annual General Meeting and the registration of both the transfer resolution and the merger in the commercial register at the seat of MorphoSys AG, as well as the registration of the merger in the commercial register at the seat of Novartis BidCo Germany AG. *** END OF AD HOC ANNOUNCEMENT End of Inside Information Information and Explanation of the Issuer to this announcement: Information and Explanation of the Issuer to this announcement: This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of MorphoSys AG. MorphoSys Forward Looking Statements[1] This communication contains certain forward-looking statements concerning MorphoSys AG (the "Company"), Novartis BidCo Germany AG and the merger squeeze-out that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions. The forward-looking statements contained in this communication represent the judgment of the Company as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of the Company, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the merger squeeze-out; the effects of the merger squeeze-out on relationships with employees, other business partners or governmental entities; that Novartis BidCo Germany AG and Novartis AG may not realize the potential benefits of the acquisition of the Company by Novartis AG; transaction costs associated with the merger squeeze-out; potential operational difficulties with integrating MorphoSys with Novartis AG; that the Company's expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; the Company's reliance on collaborations with third parties; estimating the commercial potential of the Company's development programs; and other risks indicated in the risk factors included in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this communication. The Company expressly disclaims any obligation to update any such forward-looking statements in this communication to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at and follow us on Twitter at X and LinkedIn. For more information, please contact: MorphoSys AG Dr. Julia Neugebauer Vice President, Global Investor Relations Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com 12-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
|
MorphoSys AG / 關鍵詞：擠出 根據EU) No. 596/2014條例第17段第1款披露的內部信息的發佈 關鍵詞：擠出 德國，普蘭格/慕尼黑，2024年7月12日 臨時公告：合併擠出現金補償定爲68.00歐元 MorphoSys AG（FSE：MOR；納斯達克：MOR）宣佈Novartis BidCo Germany AG向MorphoSys AG管理層提交了具體要求（konkretisiertes Verlangen），根據德國轉型法案（Umwandlungsgesetz - UmwG）第62條第1款和第5款第1句以及德國股份公司法（Aktiengesetz - AktG）第327a和以下規定，召集MorphoSys AG股東大會，決定以適當的現金補償向Novartis BidCo Germany AG轉讓MorphoSys AG少數股東持有的股份。 Novartis BidCo Germany AG目前持有MorphoSys AG股份總數的約91.04％，扣除依據UmwG第62條第1款第2句規定的自庫存的股份後，約佔MorphoSys AG股本的91.17％，因此根據UmwG第62條第5款定義，Novartis BidCo Germany AG是MorphoSys AG的主要股東。Novartis BidCo Germany AG已確定每MorphoSys AG股的現金補償金額爲68.00歐元。法庭指定的專家核數師已經表明，從目前的角度來看，他將確認現金補償是充分的。 MorphoSys AG和Novartis BidCo Germany AG之間的合併協議的最終締結和公證將很快進行。預計將於2024年8月27日舉行的MorphoSys AG股東大會上，將通過決議將MorphoSys AG少數股東的股份轉讓給Novartis BidCo Germany AG，以每股68.00歐元的現金補償。 合併擠出的有效性仍需MorphoSys AG股東大會批准，並在MorphoSys AG所在地商業註冊處登記轉讓決議和合並，以及在Novartis BidCo Germany AG所在地商業註冊處登記合併。 *** AD HOC公告結束 內部信息結束 發佈者就此公告的信息和說明： 發佈者就此公告的信息和說明： 本通訊既不是購買的要約，也不是出售MorphoSys AG股份的要約。 MorphoSys的前瞻性聲明[1] 本通信涉及MorphoSys AG (以下簡稱“公司”)、Novartis BidCo Germany AG以及併購抽逃的某些前瞻性聲明，存在重大風險和不確定性。前瞻性聲明包括任何包含“預期”、“相信”、“估計”、“期望”、“計劃”、“目標”、“可能”、“也許”、“規劃”、“預測”、“項目”、“尋求”、“目標”、“潛在”、“將會”、“可能會”的表達。 此通訊中包含的前瞻性聲明代表公司在本通訊日期的判斷，並涉及已知和未知的風險和不確定性，有可能導致公司的實際結果，財務狀況和流動性，業績或成就，或業界的結果，與任何歷史或未來的結果，財務狀況和流動性，業績或成就表現或暗示的任何實際結果，財務狀況和流動性，業績或成就均存在實質性差異。此外，即使公司的結果，業績，財務狀況和流動性以及其所在行業的發展與此類前瞻性聲明一致，也可能不預示未來期間的結果或發展。導致實際結果與預期的前瞻性聲明相差的風險和不確定性包括但不限於：合併擠出的時間不確定性；合併擠出對與員工，其他商業夥伴或政府實體之間的關係的影響；Novartis BidCo Germany AG和Novartis AG可能無法實現通過收購Novartis AG的公司獲得的潛在利益；與合併擠出相關的交易成本；整合MorphoSys和Novartis AG可能存在操作困難；公司的預期可能不正確；競爭發展，臨床試驗和產品開發活動及監管批准要求固有的不確定性；公司依賴與第三方的合作關係；估計公司開發項目的商業潛力；以及在公司的美國證券交易委員會（SEC）的備案文件中包括的風險因素。鑑於這些不確定性，建議讀者不要對此類前瞻性聲明放置任何不當的依賴。這些前瞻性聲明僅代表本通訊發佈日期的判斷。公司明確不承擔更新本通訊中此類前瞻性聲明以反映其對此類前瞻性聲明的預期是否有所變更或基於任何此類聲明所基於的事件，情況或環境的變更對實際結果與定於在前瞻性聲明中確定的結果不同的可能性的影響，除非受到法律或法規的明確要求。 關於MorphoSys 在MorphoSys，我們的使命是爲患有癌症的人提供更多生命。作爲全球商業階段的生物製藥公司，我們開發和提供創新藥物，旨在重新定義癌症的治療方式。MorphoSys總部位於德國的普蘭格，並在馬薩諸塞州波士頓擁有其美國業務。要了解更多信息，請訪問我們的網站。和我們一起Twitter at X和頁面。LinkedIn. 更多信息，請聯繫： morphosys AG 聚利a Neugebauer博士 全球投資者關係副總裁 電話：+49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com 2024年7月12日CET /CESt EQS配送服務包括監管公告，財務/企業新聞和新聞發佈。 |
| Language: | English |
| Company: | MorphoSys AG |
| Semmelweisstr. 7 | |
| 82152 Planegg | |
| Germany | |
| Phone: | +49 (0)89 899 27-0 |
| Fax: | +49 (0)89 899 27-222 |
| E-mail: | investors@morphosys.com |
| Internet: | |
| ISIN: | DE0006632003 |
| WKN: | 663200 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
| EQS News ID: | 1945449 |
| 語言： | 英語 |
| 公司: | morphosys AG |
| Semmelweisstr. 7 | |
| 82152 Planegg | |
| 德國 | |
| 電話： | 電話：+49 (0)89 899 27-0 |
| 傳真： | 傳真：+49 (0)89 899 27-222 |
| 電子郵件： | investors@morphosys.com |
| 閱讀我們的年報 | |
| ISIN代碼 ： | DE0006632003 |
| WKN： | 663200 |
| 上市： | 法蘭克福（主板）上市、柏林、杜塞爾多夫、漢堡、漢諾威、慕尼黑、斯圖加特、Tradegate Exchange非官方上市、納斯達克 |
| EQS新聞 ID： | 1945449 |
| End of Announcement | EQS News Service |
| 公告結束 | EQS新聞服務 |
譯文內容由第三人軟體翻譯。